Target intelligence / Profile preview

Human papillomavirus type 16 minor capsid protein L2 (HPV16 L2)

Target
HPV16 L2
Molecular classification
Viral structural protein, Other
01

Overview

Human papillomavirus type 16 minor capsid protein L2 (HPV16 L2) is a structural protein that plays a critical role in the early stages of viral infection, including viral entry, endosomal escape, and retrograde trafficking of the viral genome to the host cell nucleus. Unlike the major capsid protein L1, which is highly type-specific, the N-terminal region of L2 contains highly conserved epitopes (such as the RG1 epitope spanning residues 17-36) that are shared across multiple high-risk and low-risk HPV genotypes. Consequently, HPV16 L2-derived sequences are prime targets for the development of next-generation, broad-spectrum prophylactic vaccines designed to elicit cross-neutralizing antibodies. Additionally, L2-derived sequences are utilized in therapeutic vaccine candidates, such as the fusion protein TA-CIN (comprising HPV16 L2, E6, and E7), to stimulate both humoral and cellular immune responses against HPV-infected and transformed cells. While L2 alone is poorly immunogenic because it does not self-assemble into virus-like particles (VLPs), displaying L2-derived peptides on chimeric VLPs or other molecular scaffolds significantly enhances their immunogenicity and protective efficacy.

Other names
HPV16 minor capsid protein L2Human papillomavirus type 16 L2 proteinHPV16 L2-derived sequencesMinor capsid protein L2L2 protein, Human papillomavirus type 16
02

Mechanism of action

Active immunization using HPV16 L2-derived sequences induces cross-neutralizing antibodies that block viral entry and intracellular trafficking, and stimulates cellular immune responses to prevent and treat HPV-associated infections and malignancies.

03

Biological functions

Immune responseOther
04

Disease associations

InfectionCancerOther
05

Safety considerations

Injection site reactionsSystemic reactogenicityLow immunogenicity of L2 alone requiring scaffolds or adjuvantsLimited therapeutic efficacy of L2 alone without early proteins
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Anti-L2 antibody titersHPV16 DNA positivityE6/E7-specific T-cell responsesInterferon-gamma secretion

Beyond the preview

Go deeper on Human papillomavirus type 16 minor capsid protein L2 (HPV16 L2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human papillomavirus type 16 minor capsid protein L2 (HPV16 L2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call